Strong Half Year Results improve outlook for 2017
Posted by
27-Jul-2017
The first half of the year has been strong, allowing us to increase our financial guidance: revenue is now expected to reach €4.35 – 4.45 billion in 2017, recurring EBITA should increase to € 1.15 – 1.25 billion, and core earnings per share are expected in the range of € 3.70 – 4.15.
This is a sign that UCB is performing solidly, even in uncertain times. As a keen sailor, I know that one cannot always expect plain sailing but it is reassuring that the good ship UCB is solidly built and can weather heavy storms – all thanks to its skilled mariners, of course!
The report paints a picture of UCB, offering investors and other stakeholders insights into our company. For me, one of the key headlines is the fact that our five core products represents 85% of UCB’s sales.
For those looking to understand the company, it is heartening to know that if you are familiar with these five products – spread over our two key areas of expertise, neurology and immunology – you can quite swiftly understand UCB. This enhances transparency and reduces complexity, which I know many investors find appealing.
The report is also a window on the future, providing updates on our R&D pipeline and our continued commitment to bringing new products to patients in areas such as osteoporosis. It shows that we are in good shape as we sail into the second half of 2017 – and beyond.
For more information click here to read the report or contact me directly: antje.witte@ucb.com.
This is a sign that UCB is performing solidly, even in uncertain times. As a keen sailor, I know that one cannot always expect plain sailing but it is reassuring that the good ship UCB is solidly built and can weather heavy storms – all thanks to its skilled mariners, of course!
The report paints a picture of UCB, offering investors and other stakeholders insights into our company. For me, one of the key headlines is the fact that our five core products represents 85% of UCB’s sales.
For those looking to understand the company, it is heartening to know that if you are familiar with these five products – spread over our two key areas of expertise, neurology and immunology – you can quite swiftly understand UCB. This enhances transparency and reduces complexity, which I know many investors find appealing.
The report is also a window on the future, providing updates on our R&D pipeline and our continued commitment to bringing new products to patients in areas such as osteoporosis. It shows that we are in good shape as we sail into the second half of 2017 – and beyond.
For more information click here to read the report or contact me directly: antje.witte@ucb.com.
Leave a Comment